• SMAIO reported first-half 2026 sales up 3% to EUR 5.1 million, despite a four-month pause from a key U.S. surgeon.
• U.S. sales rose 10% to USD 4.5 million, or up 3% to EUR 3.9 million on a EUR 0.3 million negative FX impact.
• Second-quarter sales fell 6% to EUR 2.3 million; U.S. revenue dropped 14% to EUR 1.6 million.
• Network expansion added 5 U.S. centers; 13 new surgeons completed first implants; more than 20 centers registered by end-June.
• Cash totaled EUR 7 million at June 30, up from EUR 5.9 million at Dec. 31, 2025.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SMAIO SA published the original content used to generate this news brief on July 16, 2026, and is solely responsible for the information contained therein.